Skip to main content
Premium Trial:

Request an Annual Quote

Nanomix, Mobility Health to Develop LDT for Antibodies Against COVID-19 for Use in Mobile Labs

NEW YORK — Nanomix said Friday it is collaborating with Mobility Health on a point-of-care, laboratory-developed test to measure COVID-19 antibodies that show protection against the disease. The test is being developed for use in mobile labs.

San Leandro, California-based Nanomix will supply assay materials and Mobility Health, based in Mason, Ohio, will complete development and validation of the test. The firms plan to file for CLIA Lab Emergency Use Authorization from the US Food and Drug Administration.

Nanomix CEO Thomas Schlumpberger said in the announcement the assay will use the Nanomix eLab handheld immunoassay and chemistry diagnostic platform, which he said is ideal for rapid testing for COVID-19 antibodies.

Mobility Health CEO Sandra Gunselman added that the assay will give patients highly accurate measurements of their protection against the SARS-CoV-2 virus and help them make informed decisions.

"This offering fits extremely well with our mobile laboratory platform, while advancing our mission of providing innovative new products in the enduring fight against COVID-19 and other infectious diseases," she said.

Financial and other terms of the deal were not disclosed.